Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Decline in CIN2+ in Younger Women after HPV Vaccine

Key clinical point: The rates of CIN2+ have declined in younger women since introduction of the HPV vaccine.

Major finding: The rates of vaccine-targeted CIN2+ declined from 52% in 2008 to 30% in 2016 among women aged 18-24 years.

Study details: Analysis of data from the Human Papillomavirus Vaccine Impact Monitoring Program from 2008 to 2016.

Disclosures: One author declared personal fees from Merck during the course of the study. No other conflicts of interest were declared.


McClung N et al. MMWR. 2019 Apr 19;68:337-43.